Chiglitazar, a dual PPAR-α/γ agonist, is an effective insulin sensitivity agent used to treat the major metabolic disorders of type 2 diabetes and may bring better impacts on lipid homeostasis through different mechanisms than selective PPAR-γ agonists in diabetic patients [23]. The gene discussed is PPARG; the disease is metabolic disease.